Xenetic Biosciences Inc Net Assets
Xenetic Biosciences Inc net assets. Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) has net assets worth $6.07 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.97 Million) and total liabilities ($894.98K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore XBIO net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.07 Million |
| % of Total Assets | 87.16% |
| Annual Growth Rate | 81.43% |
| 5-Year Change | -59.79% |
| 10-Year Change | -54.26% |
| Growth Volatility | 303165.05 |
Net Assets of Xenetic Biosciences Inc (2011–2025)
Net assets of Xenetic Biosciences Inc from 2011 to 2025. This chart illustrates how Xenetic Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Xenetic Biosciences Inc to measure how much of total assets are equity-financed.
Annual Net Assets for Xenetic Biosciences Inc (2011–2025)
The table below shows the annual net assets of Xenetic Biosciences Inc from 2011 to 2025. For live market cap and overall valuation, see Xenetic Biosciences Inc (XBIO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.40 Million | +23.12% |
| 2024-12-31 | $6.01 Million | -38.67% |
| 2023-12-31 | $9.80 Million | -28.22% |
| 2022-12-31 | $13.65 Million | -25.81% |
| 2021-12-31 | $18.39 Million | +50.58% |
| 2020-12-31 | $12.22 Million | -29.03% |
| 2019-12-31 | $17.21 Million | +73.65% |
| 2018-12-31 | $9.91 Million | -30.69% |
| 2017-12-31 | $14.30 Million | -11.55% |
| 2016-12-31 | $16.17 Million | +144.67% |
| 2015-12-31 | $6.61 Million | -36.94% |
| 2014-12-31 | $10.48 Million | -16.94% |
| 2013-12-31 | $12.62 Million | -39.28% |
| 2012-12-31 | $20.78 Million | +1177162.66% |
| 2011-12-31 | $1.76K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xenetic Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19986709600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Xenetic Biosciences Inc Net Assets Breakdown (December 2025)
Xenetic Biosciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.29K | 0.03% |
| Other Comprehensive Income | $253.73K | 3.43% |
| Other Components | $207.02 Million | 2799.08% |
| Total Equity | $7.40 Million | 100.00% |
Xenetic Biosciences Inc Competitors by Market Cap
The table below lists competitors of Xenetic Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intan Baruprana Finance Tbk
JK:IBFN
|
$4.88 Million |
|
Altur Slatina
RO:ALT
|
$4.88 Million |
|
Samchai Steel Industries Public Company Limited
BK:SAM
|
$4.89 Million |
|
MEKICS Co Ltd
KQ:058110
|
$4.89 Million |
|
Altheora SA
PA:ALORA
|
$4.87 Million |
|
Astrotech Corp
NASDAQ:ASTC
|
$4.87 Million |
|
Gasporox AB (publ)
ST:GPX
|
$4.87 Million |
|
Manas Enerji Yonetimi Sanayi & Ticaret AS
IS:MANAS
|
$4.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xenetic Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,007,180 to 7,395,822, a change of 1,388,642 (23.1%).
- Net loss of 2,680,860 reduced equity.
- New share issuances of 4,004,715 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.68 Million | -36.25% |
| Share Issuances | $4.00 Million | +54.15% |
| Other Changes | $64.79K | +0.88% |
| Total Change | $- | 23.12% |
Book Value vs Market Value Analysis
This analysis compares Xenetic Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $686.90 | $2.08 | x |
| 2013-12-31 | $416.98 | $2.08 | x |
| 2014-12-31 | $305.41 | $2.08 | x |
| 2015-12-31 | $187.75 | $2.08 | x |
| 2016-12-31 | $261.13 | $2.08 | x |
| 2017-12-31 | $198.04 | $2.08 | x |
| 2018-12-31 | $131.12 | $2.08 | x |
| 2019-12-31 | $60.35 | $2.08 | x |
| 2020-12-31 | $19.11 | $2.08 | x |
| 2021-12-31 | $17.89 | $2.08 | x |
| 2022-12-31 | $9.59 | $2.08 | x |
| 2023-12-31 | $6.41 | $2.08 | x |
| 2024-12-31 | $3.90 | $2.08 | x |
| 2025-12-31 | $4.35 | $2.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xenetic Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -90.07%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.13x
- Recent ROE (-36.25%) is above the historical average (-88.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -30.46% | -2155.41% | 0.01x | 1.22x | $-8.41 Million |
| 2013 | -67.99% | -857.92% | 0.05x | 1.54x | $-9.84 Million |
| 2014 | -136.51% | 0.00% | 0.00x | 1.56x | $-15.36 Million |
| 2015 | -189.26% | 0.00% | 0.00x | 2.56x | $-13.17 Million |
| 2016 | -335.24% | -1806.87% | 0.14x | 1.30x | $-55.82 Million |
| 2017 | -25.14% | -47.40% | 0.40x | 1.34x | $-5.03 Million |
| 2018 | -73.65% | 0.00% | 0.00x | 1.46x | $-8.29 Million |
| 2019 | -74.22% | -74856.59% | 0.00x | 1.25x | $-14.50 Million |
| 2020 | -89.18% | -2493.11% | 0.03x | 1.08x | $-12.12 Million |
| 2021 | -30.69% | -486.36% | 0.06x | 1.08x | $-7.48 Million |
| 2022 | -48.01% | -383.87% | 0.12x | 1.08x | $-7.92 Million |
| 2023 | -42.21% | -162.78% | 0.24x | 1.08x | $-5.11 Million |
| 2024 | -65.93% | -158.39% | 0.36x | 1.15x | $-4.56 Million |
| 2025 | -36.25% | -90.07% | 0.36x | 1.13x | $-3.42 Million |
Industry Comparison
This section compares Xenetic Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xenetic Biosciences Inc (XBIO) | $6.07 Million | -30.46% | 0.15x | $4.87 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatmen… Read more